Progressive ankylosis protein (ank) in osteoblasts and osteoclasts controls bone formation and bone remodeling

Journal of Bone and Mineral Research

Volumn 25, Issue 8, 2010, Pages 1771-1783

  Kim, Hyon Jong ^a   Minashima, Takeshi ^a   McCarthy, Edward F ^c   Winkles, Jeffrey A ^b   Kirsch, Thorsten ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Ank; Osteoblast differentiation; Osteoclast differentiation; Skeletal phenotype; Transcription factors

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANKYLOSIS PROTEIN; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN; PYROPHOSPHATE; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MINERALIZATION; BONE REMODELING; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PROTEIN ANALYSIS; PROTEIN FUNCTION;

ANIMALS; BONE MARROW CELLS; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; CELL COUNT; CELL DIFFERENTIATION; CELL SEPARATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; FEMUR; MEMBRANE PROTEINS; MICE; MUTANT PROTEINS; ORGAN SIZE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; SKULL; STROMAL CELLS; TIBIA; TRANSCRIPTION, GENETIC;

EID: 77955748019     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.60     Document Type: Article

References (48)

1. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318-3325.
2. Stark Z, Savarirayan R. Osteopetrosis. Orphanet J Rare Dis. 2009;4:5.
3. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747-754.
4. Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755-764.
5. Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89:765-771.
6. Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108:17-29. (Pubitemid 34137009)
7. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 2006;99:1233-1239.
8. Karsenty G. Transcriptional control of skeletogenesis. Annu Rev Genomics Hum Genet. 2008;9:183-196.
9. Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr. 2009;19:61-72.
10. Roodman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci. 2006;1068:100-109.
11. Boyce BF, Yamashita T, Yao Z, Zhang Q, Li F, Xing L. Roles for NFkappaB and c-Fos in osteoclasts. J Bone Miner Metab. 2002;23 (Suppl):11-15.
12. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science. 2000;289:265-270.
13. Nurnberg P, Thiele H, Chandler D, et al. Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia. Nat Genet. 2001;28:37-41.
14. Reichenberger E, Tiziani V, Watanabe S, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68:1321-1326.
15. Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 2006;79:1017-1029.
16. Key LL Jr, Volberg F, Baron R, Anast CS. Treatment of craniometaphyseal dysplasia with calcitriol. J Pediatr. 1988;112:583-587.
17. Fanconi S, Fischer JA, Wieland P, et al. Craniometaphyseal dysplasia with increased bone turnover and secondary hyperparathyroidism: therapeutic effect of calcitonin. J Pediatr. 1988;112:587-591.
18. Millard DR Jr, Maisels DO, Batstone JH, Yates BW. Craniofacial surgery in craniometaphyseal dysplasia. Am J Surg. 1967;113:615-621.
19. Jackson WP, Albright F, Drewry G, Hanelin J, Rubin MI. Metaphyseal dysplasia, epiphyseal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling. AMA Arch Intern Med. 1954;94: 871-885.
20. Chen IP, Wang CJ, Strecker S, Koczon-Jaremko B, Boskey A, Reichenberger EJ. Introduction of a Phe377del Mutation in ANK Creates a Mouse Model for Craniometaphyseal Dysplasia. J Bone Miner Res. 2009;24:1206-1215.
21. Gurley KA, Chen H, Guenther C, et al. Mineral formation in joints caused by complete or joint-specific loss of ANK function. J Bone Miner Res. 2006;21:1238-1247.
22. Castro CH, Shin CS, Stains JP, et al. Targeted expression of a dominant-negative N-cadherin in vivo delays peak bone mass and increases adipogenesis. J Cell Sci. 2004;117:2853-2864.
23. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595-610.
24. Tashiro K, Kondo A, Kawabata K, et al. Efficient osteoblast differentiation from mouse bone marrow stromal cells with polylysin-modified adenovirus vectors. Biochem Biophys Res Commun. 2009;379:127-132.
25. Nadri S, Soleimani M, Hosseni RH, Massumi M, Atashi A, Izadpanah R. An efficient method for isolation of murine bone marrow mesenchymal stem cells. Int J Dev Biol. 2007;51:723-729. (Pubitemid 350205607)
26. Ray N, Kuwahara M, Takada Y, et al. c-Fos suppresses systemic inflammatory response to endotoxin. Int Immunol. 2006;18:671-677. (Pubitemid 43779057)
27. Zhao C, Irie N, Takada Y, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 2006;4:111-121.
28. Wang W, Kirsch T. Retinoic acid stimulates annexin-mediated growth plate chondrocyte mineralization. J Cell Biol. 2002;157:1061-1069.
29. Addison WN, Azari F, Sorensen ES, Kaartinen MT, McKee MD. Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem. 2007;282:15872-15883.
30. Sali AF, J.M./Terkeltaub,R./Goding,J.W. Germline deletion of the nucleoside triphosphate (NTPPPH) plasma cell membrane glycoprotein (PC-1) produces abnormal calcification of periarticular tissues. In: Vanduffel LL R, ed. Ecto-ATPases and related ectonucleotidases. The Netherlands: Shaker, Maastrich; 1999: pp 267-282.
31. Rutsch F, Vaingankar S, Johnson K, et al. PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol. 2001;158:543-554.
32. Terkeltaub R. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2006;2:371-377.
33. 2+ as an extracellular signal in bone. Cell Calcium. 2004;35:249-255.
34. Hoebertz A, Townsend-Nicholson A, Glass R, Burnstock G, Arnett TR. Expression of P2 receptors in bone and cultured bone cells. Bone. 2000;27:503-510.
35. Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008;23:1712-1721.
36. Beck GR Jr. Inorganic phosphate as a signaling molecule in osteoblast differentiation. J Cell Biochem. 2003;90:234-243. (Pubitemid 37222192)
37. Cecil DL, Rose DM, Terkeltaub R, Liu-Bryan R. Role of interleukin-8 in PiT-1 expression and CXCR1-mediated inorganic phosphate uptake in chondrocytes. Arthritis Rheum. 2005;52:144-154.
38. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005;96:717-722. (Pubitemid 40559510)
39. Hayashibara T, Hiraga T, Sugita A, et al. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res. 2007;22:1743-1751.
40. Takeda E, Taketani Y, Morita K, et al. Molecular mechanisms of mammalian inorganic phosphate homeostasis. Adv Enzyme Regul. 2000;40:285-302.
41. i transport in osteogenic cells for bone metabolism. Kidney Int. 1996;49:975-980.
42. Winslow MM, Pan M, Starbuck M, et al. Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell. 2006;10:771-782. (Pubitemid 43779111)
43. Saita Y, Takagi T, Kitahara K, et al. Lack of Schnurri-2 expression associates with reduced bone remodeling and osteopenia. J Biol Chem. 2007;282:12907-12915.
44. Kawamura N, Kugimiya F, Oshima Y, et al. Akt1 in osteoblasts and osteoclasts controls bone remodeling. PLoS ONE. 2007;2:e1058.
45. Finkelman RD, Eason AL, Rakijian DR, Tutundzhyan Y, Hardesty RA. Elevated IGF-II and TGF-beta concentrations in human calvarial bone: potential mechanism for increased graft survival and resistance to osteoporosis. Plast Reconstr Surg. 1994;93:732-738.
46. Wang J, Tsui HW, Beier F, Tsui FW. The CPPDD-Associated ANKH M48T Mutation Interrupts the Interaction of ANKH with the Sodium/Phosphate Cotransporter PiT-1. J Rheumatol. 2009;36:1265-1272.
47. Zaka R, Stokes D, Dion AS, Kusnierz A, Han F, Williams CJ. P5L mutation in Ank results in an increase in extracellular inorganic pyrophosphate during proliferation and nonmineralizing hypertrophy in stably transduced ATDC5 cells. Arthritis Res Ther. 2006;8: R164.
48. Mozar A, Haren N, Chasseraud M, et al. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells. J Cell Physiol. 2008;215:47-54.